Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Significance of TIM-3 Expression in Resected Esophageal Squamous Cell Carcinoma

(2020) Yuhuan Zhao et al.   ANNALS OF THORACIC SURGERY

HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma

(2020) Qiang-Hua Zhou et al.   Journal for ImmunoTherapy of Cancer

Expression patterns of immune checkpoints in acute myeloid leukemia

(2020) Cunte Chen et al.   Journal of Hematology & Oncology

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma

(2020) Yoshifumi Baba et al.   CANCER SCIENCE

Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

(2020) Zhaopei Liu et al.   Journal for ImmunoTherapy of Cancer

TIGIT in cancer immunotherapy

(2020) Joe-Marc Chauvin et al.   Journal for ImmunoTherapy of Cancer

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets

(2019) Maximilian Stahl et al.   Current Oncology Reports

CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy

(2019) Delong Liu   Journal of Hematology & Oncology

Epidemiology of Esophageal Squamous Cell Carcinoma

(2018) Christian C. Abnet et al.   GASTROENTEROLOGY

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration

(2018) Willi Sauerbrei et al.   JNCI-Journal of the National Cancer Institute

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration

(2018) Willi Sauerbrei et al.   JNCI-Journal of the National Cancer Institute

Immune checkpoint blockade therapy for esophageal squamous cell carcinoma

(2018) Kazuto Harada et al.   Journal of Thoracic Disease

TIM-3, a promising target for cancer immunotherapy

(2018) Yayi He et al.   OncoTargets and Therapy

Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma

(2018) Jing-Jing Zhao et al.   Cancer Management and Research

Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma

(2017) Chun-yu Huang et al.   JOURNAL OF IMMUNOTHERAPY

Oesophageal cancer

(2017) Jesper Lagergren et al.   LANCET

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

Esophageal Carcinoma

(2014) Anil K. Rustgi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Factors and Outcome for Patients with Esophageal Squamous Cell Carcinoma Underwent Surgical Resection Alone: Evaluation of the Seventh Edition of the American Joint Committee on Cancer Staging System for Esophageal Squamous Cell Carcinoma

(2013) Shao-bin Chen et al.   Journal of Thoracic Oncology

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE